LOS ANGELES, June 23 /CNW/ - Canopus BioPharma, Inc. (OTC: CBIA), is
pleased to announce that the South African Medicines Control Council has
granted approval for a Phase II study in 30 cancer patients evaluating the
protective effect of CB1400 on the gastrointestinal tract from
radiation-induced mucositis. This new trial is an important step forward in
the development of CB1400 as a novel, preventative, anti-mucositis agent.
Oral and gastrointestinal (GI) mucositis is a painful, debilitating, and
sometimes fatal, side-effect of radiation therapy and cancer chemotherapy. No
preventative mucositis medicines are available, and few treatments are
effective. With some cancer therapies, oral mucositis can develop in over 90%
of patients. Consequently, it is a widespread problem with considerable
economic and healthcare implications. There is a real need for an effective
and well-tolerated mucositis prophylactic. The US market for a preventative
mucositis agent is estimated to be over $1 billion per annum.
In work carried out on behalf of Canopus, CB1400 has already been shown
to have protective and antimutagenic effects when tested in an animal model of
mucositis. Complete protection of the GI tract was seen in gamma-radiated mice
pre-treated with oral CB1400 (100 mg/kg/day). Even with high doses of
radiation (10Gy), there was no evidence of mucositis: weight gain was observed
in the CB1400 pre-treated groups; all mice treated with placebo died.
Canopus BioPharma Inc. has applied to undertake further clinical studies
with leading oncologists in Australia, South Africa and the USA, investigating
CB1400 as a preventative mucositis agent in head and neck cancer patients who
are receiving radiation and/or chemotherapy.
About Canopus BioPharma, Inc.:
Canopus BioPharma, Inc. (OTCBB: CBIA) is dedicated to providing the
safest, most cost effective and efficacious pharmaceutical products and assay
methods in the areas of infectious disease, radiation protection, cancer, and
addiction. With innovative science, proven research and development
leadership, and superior products and compounds, Canopus BioPharma has, since
2001, been committed to becoming a market trend setter in a new era of
healthcare. In addition, the Company is a world leader in the development of
novel camelid antibody products to provide unique avenues of progress and
improvement in assay methods and monitoring capabilities for physicians,
patients and researchers, particularly for food chain protection applications.
Canopus maintains staff in Australia, South Africa, Ireland, Panama and the
USA. Additional information on the Company is available at
For further information:
For further information: Canopus BioPharma Contact: Len Rothstein,
President, Tel. (818) 980-5008, Fax. (818) 980-5088, email@example.com